Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at 2019 ASCO Genitourinary Cancer Symposium

by NASDAQ Market News February 16, 2019

NASDAQ Market News
Click here to email author

Medtronic Announces Preliminary PRODIGY Results: a Global Study to Identify Patients at High Risk for Opioid-Induced Respiratory Compromise

Generex Biotechnology Announces Investor Conference Call Agenda; Tuesday, February 26, at 11:00 A.M. Eastern

Ads